VEGFA and prostate neoplasm: Parenteral administration of the anisamide-targeted formulation in a mouse prostate tumour model demonstrated significant tumour inactivation and reduction in the level of vascular endothelial growth factor (VEGF) mRNA and low toxicity [122].